239 related articles for article (PubMed ID: 20004082)
1. Update on melanocortin interventions for cachexia: progress toward clinical application.
DeBoer MD
Nutrition; 2010 Feb; 26(2):146-51. PubMed ID: 20004082
[TBL] [Abstract][Full Text] [Related]
2. Melanocortin interventions in cachexia: how soon from bench to bedside?
DeBoer MD
Curr Opin Clin Nutr Metab Care; 2007 Jul; 10(4):457-62. PubMed ID: 17563464
[TBL] [Abstract][Full Text] [Related]
3. Therapy insight: Use of melanocortin antagonists in the treatment of cachexia in chronic disease.
DeBoer MD; Marks DL
Nat Clin Pract Endocrinol Metab; 2006 Aug; 2(8):459-66. PubMed ID: 16932335
[TBL] [Abstract][Full Text] [Related]
4. Genetic and pharmacologic blockade of central melanocortin signaling attenuates cardiac cachexia in rodent models of heart failure.
Scarlett JM; Bowe DD; Zhu X; Batra AK; Grant WF; Marks DL
J Endocrinol; 2010 Jul; 206(1):121-30. PubMed ID: 20371568
[TBL] [Abstract][Full Text] [Related]
5. Melanocortin-4 receptor antagonist TCMCB07 ameliorates cancer- and chronic kidney disease-associated cachexia.
Zhu X; Callahan MF; Gruber KA; Szumowski M; Marks DL
J Clin Invest; 2020 Sep; 130(9):4921-4934. PubMed ID: 32544087
[TBL] [Abstract][Full Text] [Related]
6. The use of melanocortin antagonists in cachexia of chronic disease.
Scarlett JM; Marks DL
Expert Opin Investig Drugs; 2005 Oct; 14(10):1233-9. PubMed ID: 16185165
[TBL] [Abstract][Full Text] [Related]
7. Cachexia: lessons from melanocortin antagonism.
Deboer MD; Marks DL
Trends Endocrinol Metab; 2006 Jul; 17(5):199-204. PubMed ID: 16750633
[TBL] [Abstract][Full Text] [Related]
8. Melanocortin-4 receptor antagonists as potential therapeutics in the treatment of cachexia.
Foster AC; Chen C
Curr Top Med Chem; 2007; 7(11):1131-6. PubMed ID: 17584133
[TBL] [Abstract][Full Text] [Related]
9. Treatment of cachexia: melanocortin and ghrelin interventions.
Steinman J; DeBoer MD
Vitam Horm; 2013; 92():197-242. PubMed ID: 23601426
[TBL] [Abstract][Full Text] [Related]
10. Melanocortin antagonism ameliorates muscle wasting and inflammation in chronic kidney disease.
Cheung WW; Mak RH
Am J Physiol Renal Physiol; 2012 Nov; 303(9):F1315-24. PubMed ID: 22914778
[TBL] [Abstract][Full Text] [Related]
11. MC4 receptor antagonists: a potential treatment for cachexia.
Foster AC; Chen C; Markison S; Marks DL
IDrugs; 2005 Apr; 8(4):314-9. PubMed ID: 15800806
[TBL] [Abstract][Full Text] [Related]
12. The regulation of feeding and metabolic rate and the prevention of murine cancer cachexia with a small-molecule melanocortin-4 receptor antagonist.
Markison S; Foster AC; Chen C; Brookhart GB; Hesse A; Hoare SR; Fleck BA; Brown BT; Marks DL
Endocrinology; 2005 Jun; 146(6):2766-73. PubMed ID: 15774557
[TBL] [Abstract][Full Text] [Related]
13. Orally available selective melanocortin-4 receptor antagonists stimulate food intake and reduce cancer-induced cachexia in mice.
Weyermann P; Dallmann R; Magyar J; Anklin C; Hufschmid M; Dubach-Powell J; Courdier-Fruh I; Henneböhle M; Nordhoff S; Mondadori C
PLoS One; 2009; 4(3):e4774. PubMed ID: 19295909
[TBL] [Abstract][Full Text] [Related]
14. Neural control of the anorexia-cachexia syndrome.
Laviano A; Inui A; Marks DL; Meguid MM; Pichard C; Rossi Fanelli F; Seelaender M
Am J Physiol Endocrinol Metab; 2008 Nov; 295(5):E1000-8. PubMed ID: 18713954
[TBL] [Abstract][Full Text] [Related]
15. Exploiting the therapeutic potential of leptin signaling in cachexia.
Mak RH; Cheung WW; Gertler A
Curr Opin Support Palliat Care; 2014 Dec; 8(4):352-7. PubMed ID: 25259544
[TBL] [Abstract][Full Text] [Related]
16. Neuropeptides in the pathophysiology and treatment of cachexia.
Krasnow SM; Marks DL
Curr Opin Support Palliat Care; 2010 Dec; 4(4):266-71. PubMed ID: 20733497
[TBL] [Abstract][Full Text] [Related]
17. Anticatabolic properties of melanocortin-4 receptor antagonists.
Madison LD; Marks DL
Curr Opin Clin Nutr Metab Care; 2006 May; 9(3):196-200. PubMed ID: 16607116
[TBL] [Abstract][Full Text] [Related]
18. Advances in understanding and treating cardiac cachexia: highlights from the 5th Cachexia Conference.
von Haehling S; Stepney R; Anker SD
Int J Cardiol; 2010 Oct; 144(3):347-9. PubMed ID: 20561693
[TBL] [Abstract][Full Text] [Related]
19. Peripheral administration of the melanocortin-4 receptor antagonist NBI-12i ameliorates uremia-associated cachexia in mice.
Cheung WW; Kuo HJ; Markison S; Chen C; Foster AC; Marks DL; Mak RH
J Am Soc Nephrol; 2007 Sep; 18(9):2517-24. PubMed ID: 17687077
[TBL] [Abstract][Full Text] [Related]
20. Differential role of melanocortin receptor subtypes in cachexia.
Marks DL; Butler AA; Turner R; Brookhart G; Cone RD
Endocrinology; 2003 Apr; 144(4):1513-23. PubMed ID: 12639936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
